Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
22
04
2022
received:
07
02
2022
accepted:
16
05
2022
pubmed:
22
5
2022
medline:
16
11
2022
entrez:
21
5
2022
Statut:
ppublish
Résumé
Cholestasis is associated with disease severity and worse outcome in COVID-19. Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been described. Hospitalized patients with COVID-19 between 03/2020 and 07/2021 were included. Patients were stratified as having (i) no chronic liver disease (CLD), (ii) non-advanced CLD (non-ACLD), or (iii) advanced CLD (ACLD). Patients with CLD and non-COVID-19 pneumonia were matched to patients with CLD and COVID-19 as a control cohort. Liver chemistries before (Pre) and at first, second, and third blood withdrawal after SARS-CoV-2 infection (T1-T3) and at last available time point (last) were recorded. A total of 496 patients were included. In total, 13.1% (n = 65) had CLD (non-ACLD: 70.8%; ACLD: 29.2%); the predominant etiology was NAFLD/NASH (60.0%). COVID-19-related liver injury was more common among patients with CLD (24.6% vs. 10.6%; p = 0.001). After SARS-CoV-2 infection, patients with CLD exhibited progressive cholestasis with persistently increasing levels of alkaline phosphatase (Pre: 91.0 vs. T1: 121.0 vs. last: 175.0 U/L; p < 0.001) and gamma-glutamyl transferase (Pre: 95.0 vs. T1: 135.0 vs. last: 202.0 U/L; p = 0.001). A total of 23.1% of patients with CLD (n = 15/65) developed cholestatic liver failure (cholestasis plus bilirubin ≥6 mg/dl) during COVID-19, and 15.4% of patients (n = 10/65) developed SSC. SSC was significantly more frequent among patients with CLD and COVID-19 than in patients with CLD and non-COVID-19 pneumonia (p = 0.040). COVID-19-associated SSC occurred predominantly in patients with NAFLD/NASH and metabolic risk factors. A total of 26.3% (n = 5/19) of patients with ACLD experienced hepatic decompensation after SARS-CoV-2 infection. About 20% of patients with CLD develop progressive cholestasis after SARS-CoV-2 infection. Patients with NAFLD/NASH and metabolic risk factors are at particular risk for developing cholestatic liver failure and/or SSC after COVID-19.
Sections du résumé
BACKGROUND AND AIMS
Cholestasis is associated with disease severity and worse outcome in COVID-19. Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been described.
APPROACH AND RESULTS
Hospitalized patients with COVID-19 between 03/2020 and 07/2021 were included. Patients were stratified as having (i) no chronic liver disease (CLD), (ii) non-advanced CLD (non-ACLD), or (iii) advanced CLD (ACLD). Patients with CLD and non-COVID-19 pneumonia were matched to patients with CLD and COVID-19 as a control cohort. Liver chemistries before (Pre) and at first, second, and third blood withdrawal after SARS-CoV-2 infection (T1-T3) and at last available time point (last) were recorded. A total of 496 patients were included. In total, 13.1% (n = 65) had CLD (non-ACLD: 70.8%; ACLD: 29.2%); the predominant etiology was NAFLD/NASH (60.0%). COVID-19-related liver injury was more common among patients with CLD (24.6% vs. 10.6%; p = 0.001). After SARS-CoV-2 infection, patients with CLD exhibited progressive cholestasis with persistently increasing levels of alkaline phosphatase (Pre: 91.0 vs. T1: 121.0 vs. last: 175.0 U/L; p < 0.001) and gamma-glutamyl transferase (Pre: 95.0 vs. T1: 135.0 vs. last: 202.0 U/L; p = 0.001). A total of 23.1% of patients with CLD (n = 15/65) developed cholestatic liver failure (cholestasis plus bilirubin ≥6 mg/dl) during COVID-19, and 15.4% of patients (n = 10/65) developed SSC. SSC was significantly more frequent among patients with CLD and COVID-19 than in patients with CLD and non-COVID-19 pneumonia (p = 0.040). COVID-19-associated SSC occurred predominantly in patients with NAFLD/NASH and metabolic risk factors. A total of 26.3% (n = 5/19) of patients with ACLD experienced hepatic decompensation after SARS-CoV-2 infection.
CONCLUSIONS
About 20% of patients with CLD develop progressive cholestasis after SARS-CoV-2 infection. Patients with NAFLD/NASH and metabolic risk factors are at particular risk for developing cholestatic liver failure and/or SSC after COVID-19.
Identifiants
pubmed: 35596929
doi: 10.1002/hep.32582
pmc: PMC9347407
pii: 01515467-202212000-00004
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1563-1575Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, et al. A guide to COVID‐19: a global pandemic caused by the novel coronavirus SARS‐CoV‐2. FEBS J. 2020;287:3633–50.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID‐19): a review. JAMA. 2020;324:782–93.
Nardo AD, Schneeweiss‐Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID‐19. Liver Int. 2021;41:20–32.
Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid‐19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
Onder G, Rezza G, Brusaferro S. Case‐fatality rate and characteristics of patients dying in relation to COVID‐19 in Italy. JAMA. 2020;323:1775–6.
Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS‐CoV‐2 infection of the liver directly contributes to hepatic impairment in patients with COVID‐19. J Hepatol. 2020;73:807–16.
Herta T, Berg T. COVID‐19 and the liver ‐ lessons learned. Liver Int. 2021;41(Suppl 1):1–8.
Brevini T, Maes M, Webb GJ, Gelson WTH, Forrest S, Mlcochova P, et al. FXR inhibition reduces ACE2 expression, SARS‐CoV‐2 infection and may improve COVID‐19 outcome. bioRxiv. 2021. https://doi.org/10.1101/2021.06.06.446781
doi: 10.1101/2021.06.06.446781
Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID‐19 and the liver. J Hepatol. 2020;73:1231–40.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40:998–1004.
Garrido I, Liberal R, Macedo G. Review article: COVID‐19 and liver disease‐what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52:267–75.
Bertolini A, van de Peppel IP, Bodewes F, Moshage H, Fantin A, Farinati F, et al. Abnormal liver function tests in patients with COVID‐19: relevance and potential pathogenesis. Hepatology. 2020;72:1864–72.
Yadav DK, Singh A, Zhang Q, Bai X, Zhang W, Yadav RK, et al. Involvement of liver in COVID‐19: systematic review and meta‐analysis. Gut. 2021;70:807–9.
Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta‐analysis: liver manifestations and outcomes in COVID‐19. Aliment Pharmacol Ther. 2020;52:584–99.
Parasa S, Desai M, Thoguluva Chandrasekar V, Patel HK, Kennedy KF, et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta‐analysis. JAMA Netw Open. 2020;3:e2011335.
Hartl L, Haslinger K, Angerer M, Jachs M, Simbrunner B, Bauer DJM, et al. Age‐adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID‐19 patients. Liver Int. 2022. https://doi.org/10.1111/liv.15274
doi: 10.1111/liv.15274
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.
Amin M. COVID‐19 and the liver: overview. Eur J Gastroenterol Hepatol. 2021;33:309–11.
Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID‐19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75:1742–52.
Ding ZY, Li GX, Chen L, Shu C, Song J, Wang W, et al. Association of liver abnormalities with in‐hospital mortality in patients with COVID‐19. J Hepatol. 2021;74:1295–302.
Bernstein D, Roth N, Kim A, Epstein M, Hirschwerk D, Kvasnovsky CL, et al. Presentation, patterns and predictive value of baseline liver tests on outcomes in COVID‐19 patients without chronic liver disease. World J Gastroenterol. 2021;27:7350–61.
Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, et al. Longitudinal association between markers of liver injury and mortality in COVID‐19 in China. Hepatology. 2020;72:389–98.
Roth NC, Kim A, Vitkovski T, Xia J, Ramirez G, Bernstein D, et al. Post‐COVID‐19 cholangiopathy: a novel entity. Am J Gastroenterol. 2021;116:1077–82.
Durazo FA, Nicholas AA, Mahaffey JJ, Sova S, Evans JJ, Trivella JP, et al. Post‐Covid‐19 cholangiopathy‐a new indication for liver transplantation: a case report. Transplant Proc. 2021;53:1132–7.
Edwards K, Allison M, Ghuman S. Secondary sclerosing cholangitis in critically ill patients: a rare disease precipitated by severe SARS‐CoV‐2 infection. BMJ Case Rep. 2020;13:e237984.
Bütikofer S, Lenggenhager D, Wendel Garcia PD, Maggio EM, Haberecker M, Reiner CS, et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID‐19. Liver Int. 2021;41:2404–17.
Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159:768–71.e3.
Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, et al. High rates of 30‐day mortality in patients with cirrhosis and COVID‐19. J Hepatol. 2020;73:1063–71.
Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, et al. Impact of COVID‐19 on the care of patients with liver disease: EASL‐ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020;2:100169.
Hartl L, Jachs M, Simbrunner B, Bauer DJM, Semmler G, Gompelmann D, et al. Cirrhosis‐associated RAS‐inflammation‐coagulation axis anomalies: parallels to severe COVID‐19. J Pers Med. 2021;11:1264.
Marjot T, Moon AM, Cook JA, Abd‐Elsalam S, Aloman C, Armstrong MJ, et al. Outcomes following SARS‐CoV‐2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74:567–77.
Huang R, Zhu L, Wang J, Xue L, Liu L, Yan X, et al. Clinical features of COVID‐19 patients with nonalcoholic fatty liver disease. Hepatol Commun. 2020;4:1758–68.
Gudnason HO, Björnsson ES. Secondary sclerosing cholangitis in critically ill patients: current perspectives. Clin Exp Gastroenterol. 2017;10:105–11.
Jaeger C, Mayer G, Henrich R, Gossner L, Rabenstein T, May A, et al. Secondary sclerosing cholangitis after long‐term treatment in an intensive care unit: clinical presentation, endoscopic findings, treatment, and follow‐up. Endoscopy. 2006;38:730–4.
Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, et al. Hypoxia‐induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002;35:1010–21.
Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013;59:583–94.
Wong GLH, Tam YH, Ng CF, Chan AWH, Choi PCL, Chu WCW, et al. Liver injury is common among chronic abusers of ketamine. Clin Gastroenterol Hepatol. 2014;12:1759–62.e1.
Zangrillo A, Landoni G, Biondi‐Zoccai G, Greco M, Greco T, Frati G, et al. A meta‐analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc. 2013;15:172–8.
Lo RSC, Krishnamoorthy R, Freeman JG, Austin AS. Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series. Singapore Med J. 2011;52:e52–5.
Noppers IM, Niesters M, Aarts L, Bauer MCR, Drewes AM, Dahan A, et al. Drug‐induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain. 2011;152:2173–8.
Seto WK, Ng M, Chan P, Ng IO, Cheung SC, Hung IF, et al. Ketamine‐induced cholangiopathy: a case report. Am J Gastroenterol. 2011;106:1004–5.
Yang L, Han Y, Nilsson‐Payant BE, Gupta V, Wang P, Duan X, et al. A human pluripotent stem cell‐based platform to study SARS‐CoV‐2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27:125–36.e7.
Horvatits T, Drolz A, Trauner M, Fuhrmann V. Liver injury and failure in critical illness. Hepatology. 2019;70:2204–15.
Geier A, Fickert P, Trauner M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:574–85.
Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol. 2013;58:155–68.